Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

NCT06749925 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

186

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

BIOLOGICAL: Dendritic Cell Vaccine
COMBINATION_PRODUCT: Pembrolizumab
OTHER: Placebo

Sponsor

University of Sao Paulo General Hospital